Abstract: The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel; packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel for enclosure of the packing material. In a particular embodiment, the apparatus is a packed bed apparatus. The methods include production of emulsion based microparticles containing a biological or chemical agent. The usefulness of the present invention is that the apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is capable of being conveniently scaled up while providing predictable emulsion properties.

Abstract: There is provided use of a mixed metal compound in the manufacture of medicament for neutralizing or buffering stomach acid, wherein the mixed metal compound contains at least one trivalent metal selected from iron (III) and aluminum and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, wherein (A) the mixed metal compound is of formula (I): MII1-aMIIIaObAn?c.zH2O (I) where MII is the at least one bivalent metal; MIII is the at least one trivalent metal; An? at least one n-valent anion; 2+a=2b+?cn and ?cn<0.9a, and z is 2 or less, and/or (B) the mixed metal compound is provided in the form of a granular material comprising (i) at least 50% by weight, based on the weight of the granular material, of the mixed metal compound (ii) from 3 to 12% by weight, based on the weight of the granular material, of non-chemically bound water, and (iii) no greater than 47% by weight based on the weight of the granular material of excipient.

Abstract: In one aspect, the present invention relates to a method of making multi-phase particles that include nanoparticulates and matrix, which maintains the nanoparticulates in a dispersed state. A flowing gas dispersion is generated that includes droplets of a precursor medium dispersed in a gas phase. The precursor medium contains liquid vehicle and at least a first precursor to a first material and a second precursor to a second material. The multi-phase particles are formed from the gas dispersion by removing at least a portion of the liquid vehicle from the droplets of precursor medium. The nanoparticulates in the multi-phase particles include the first material and the matrix in the multi-phase particles includes the second material.

Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

Abstract: The present invention relates to mixed metal compounds having pharmaceutical activity, especially as phosphate binders. It also extends to methods of manufacture of those compounds, as well as to pharmaceutical compositions containing such compounds. It further relates to their pharmaceutical use. In particular, the present invention relates to use of compounds of Formula (I): MII1-aMIIIa wherein M? is at least one bivalent metal (i.e. with two positive charges); M1 is at least one trivalent metal (i.e. with three positive charges); and 1>a>0.4.

Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: Disclosed is a composition that comprises an effective proportion of a first metal oxide powder having a primary particle size and a secondary particle size selected for the first metal oxide powder to attenuate UV A and an effective proportion of a second metal oxide powder having a secondary particle size selected for the second metal oxide powder to attenuate UVB. The mean secondary particle size of the first metal oxide powder is greater than the mean secondary particle size of the second metal oxide powder. In one embodiment, the first and the second metal oxide powders are both zinc oxide.

Abstract: A method of alleviating or treating a condition which can be alleviated or treated by administering hyoscyamine comprises administering to a subject in need thereof a pharmaceutical dosage form which comprises at least one of hyoscyamine and a pharmaceutically acceptable salt thereof. The dosage form comprises two or more hyoscyamine formulations, at least one of the formulations being an immediate release formulation and at least one other one being a controlled release formulation.

Abstract: This can provide a volatile disinfectant produced by bubbling ozone gas into a volatile solvent, the volatile solvent containing at least one volatile liquid paraffin, one volatile silicone oil, or a mixture thereof as a base under stirring the volatile solvent to thereby allow the volatile solvent to contain the ozone gas, the volatile disinfectant characterized in that, when applied to an object, the volatile disinfectant inactivates pathogens on the object and then volatilizes from the object.

Abstract: A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.

Abstract: A method of applying makeup to a surface, such as the skin, the nails, hair, or the lips, is disclosed. The method includes manually depositing, using a non-magnetic cosmetic applicator, at least a first cosmetic composition in the fluid state on the surface, the first composition containing magnetic particles that are movable under the effect of a magnetic field; and manually exposing at least part of the first composition to a magnetic device producing a magnetic field, the magnetic device located above the first composition so as to orientate and/or displace at least a fraction of the magnetic particles so as to form at least one pattern according to magnetic field lines of the magnetic field without making contact with the first composition.

Abstract: The present invention relates to a method of applying makeup to keratinous substances, in particular the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on the surface to be made up, the cosmetic composition comprising: bodies that present non-zero magnetic susceptibility and that are movable under the effect of a magnetic field; and at least one interferential pigment; and exposing at least part of the composition to a magnetic field, so as to modify the orientation and/or displace at least some of the magnetic bodies.

Abstract: A method for stabilizing conjugates between macromolecule and nanoparticle by forming a thin reinforcement layer over the surface of a nanoparticle after macromolecule chains have attached to the surface of the nanoparticle. The stabilized conjugates can be used in a wide range of applications such as in vitro diagnostics, in vivo imaging and therapeutics, which need to be conducted under various severe or harsh conditions.

Abstract: The present invention provides a banding composition for hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base comprising (1) low viscosity HPMC; (2) a component selected from the group consisting of methanol, ethanol, isopropanol, 1-propanol, acetone and/or ethyl acetate; (3) a surfactant; and (4) water; and a method for banding hard capsules using hydroxypropylmethyl cellulose as a base by using the banding composition described.

Abstract: According to an aspect of the present invention, various medical devices, including implantable or insertable medical devices, are provided, which comprise at least one particle-containing region whose surface is at least partially coated with a diamond-like coating.

Abstract: The present disclosure is directed to compounds of the structure (X): CoreL-NHE)n??(X) wherein: n is 2 or 3; NHE has the structure wherein: R1 is H or —SO2—NR7R8—; R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and —NR7R8; R3 is hydrogen; R7 is hydrogen; R8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(?O)—, —NHC(?O)NH— and —NHSO2—; and Y is selected from the group consisting of a bond, optionally substituted C1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH2)1-6O(CH2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.

Abstract: The present invention relates to a deodorant composition containing (a) a polyphenol compound or a plant extract containing a polyphenol compound, (b) a basic substance, and (c) a metal salt. The deodorant composition of the present invention is capable of providing a deodorizing effect in a short period of time when it is applied to a malodor source, is capable of providing an excellent deodorizing activity and is also excellent in the store stability.

Abstract: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.